AIM ImmunoTech Company Leadership

AIM ImmunoTech Management Team Effectiveness

The company has Return on Asset of (0.9542) % which means that on every $100 spent on assets, it lost $0.9542. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (31.3891) %, meaning that it generated no profit with money invested by stockholders. AIM ImmunoTech's management efficiency ratios could be used to measure how well AIM ImmunoTech manages its routine affairs as well as how well it operates its assets and liabilities. At this time, AIM ImmunoTech's Return On Capital Employed is very stable compared to the past year. As of the 5th of January 2026, Return On Equity is likely to grow to 12.38, though Return On Tangible Assets are likely to grow to (3.15). At this time, AIM ImmunoTech's Non Current Assets Total are very stable compared to the past year. As of the 5th of January 2026, Intangible Assets is likely to grow to about 3.1 M, while Other Current Assets are likely to drop about 217.4 K. As of the 5th of January 2026, Common Stock Shares Outstanding is likely to grow to about 676.4 K, while Net Loss is likely to drop (20.9 M). AIM ImmunoTech shows 3.85 percent of its outstanding shares held by insiders and 4.93 percent owned by other corporate entities. Some institutional investors establish a significant position in stocks such as AIM ImmunoTech in order to find ways to drive up its value. Retail investors, on the other hand, need to know that institutional holders can own millions of shares of AIM ImmunoTech, and when they decide to sell, the stock will often sell-off, which may instantly impact shareholders' value. So, traders who get in early or near the beginning of the institutional investor's buying cycle could potentially generate profits.

AIM ImmunoTech Workforce Comparison

AIM ImmunoTech Insider Trading

AIM ImmunoTech Notable Stakeholders

String symbol = request.getParameter("s");

The success or failure of an entity such as AIM ImmunoTech often depends on how effective the management is. AIM ImmunoTech management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of AIM management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the AIM management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in AIM ImmunoTech. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. To learn how to invest in AIM Stock, please use our How to Invest in AIM ImmunoTech guide.You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of AIM ImmunoTech. If investors know AIM will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about AIM ImmunoTech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

The market value of AIM ImmunoTech is measured differently than its book value, which is the value of AIM that is recorded on the company's balance sheet. Investors also form their own opinion of AIM ImmunoTech's value that differs from its market value or its book value, called intrinsic value, which is AIM ImmunoTech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because AIM ImmunoTech's market value can be influenced by many factors that don't directly affect AIM ImmunoTech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between AIM ImmunoTech's value and its price as these two are different measures arrived at by different means. Investors typically determine if AIM ImmunoTech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, AIM ImmunoTech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.